Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
STUNIC is a branded generic small molecule medication developed and manufactured by the Indonesian pharmaceutical company Triman. Its active ingredient is ambroxol hydrochloride (30 mg), a mucolytic and secretolytic agent. STUNIC functions by breaking down the structure of thick mucus in the respiratory tract, reducing its viscosity, and stimulating the production of pulmonary surfactant. These actions facilitate the clearance of secretions and improve breathing in patients with respiratory conditions. It is primarily indicated for the treatment of acute and chronic respiratory tract disorders, including bronchial asthma and exacerbations of bronchitis. The drug is approved and marketed in Indonesia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on STUNIC.